Secretariat Time Programme
12:00 - 13:30


Laboratory of Pharmaceutical Biotechnology & Molecular Diagnostics

Approved by the University of Patras, Ministry of Education pending approval






  1. KLK5 drug target in skin

Book Chapter

Pharmacological targeting of the human tissue kallikrein-related peptidases.
Pampalakis G, Sotiropoulou G. (2012) In "Proteinases as Drug Targets", pp 199-228. Edited by Ben M. Dunn, Royal Society of Chemistry (RSC), RSC Drug Discovery, UK, RSC Publishing.   


  1. KLK cascades in normal physiology and disease states (& link: )
  2. Tumor protective role for KLK6 in breast cancer
  3. Epigenetic silencing of KLK6 in breast cancer-Modes of pharmacological modulation
  4. The “expanded” integrated circuit of the cancer-cell  
  5. The human kallikrein gene cluster
  6. Crystal structure of pro-KLK6 at 1,8 Α
  7. New technologies - Proteomic profiling 


  • Cancer models
  • Transgenic mouse models


  • SKIN DISEASES: Unraveling the roles of KLK proteases in overdesquamating and inflammatory skin pathologies characterized by defective epidermal barrier. Rare skin syndromes: Proof-of-principle for pharmacological targeting
  • PARKINSON DISEASE: Investigating proteolytic pathways for pharmacological targeting KLK proteases in cancer development and progression
  • CANCER: KLK proteases in cancer development and progression
  • VENOMICS: Mining snake venoms for novel pharmaceutical proteins

Current/Recent Funding

  • ERA-NET/E-Rare-3: Joint Translational Call (2015) for "European Research Projects on Rare Diseases". Project Title: "Tracing the untackled facets of Peeling Skin Disease-Targeting epidermal proteolysis for treatment" (Propekal5) [2015-2018, PI: GSotiropoulou] Total/Partner 1 Budget: €469,197 / €100,000
  • Europa Nostra2014; Greece-France Bilateral Cooperation Project 2013-2015. Project Title: "Integration of novel mouse models to advance understanding of epidermal proteolysis in rare genetic skin diseases such as the Netherton Syndrome-Basic and translational aspects" [ERADISK5, PI: GSotiropoulou] Budget: €30,000
  • Parkinson's Disease Foundation (PDF), International Research Grants Program (IRGP), NY, USA; Project Title: "Novel insights into the properties and fate of naturally secreted alpha-synuclein" [2014-2016, PI: GS] Budget: $165,000
  • 2013 Fondation Santé Grants: "Is KLK6 protease the eluded regulator of extracellular α-synuclein?" [2013-2015, PI: GSotiropoulou] Budget: €40,000
  • Excellence Postdoctoral Grants (LS4-2139, Skink5) "Delineation of KLK5-mediated proteolytic pathways in skin desquamation" [2011-2014, PI: GSotiropoulou] Budget: €150,000

Current Research Interests

  • Molecular mechanisms underlying cancer development, invasion and metastasis-Identification of genes/proteins for targeted pharmaceutical compounds and/or molecular diagnostics.
  • Proteases and protease inhibitors (proteins/peptides, LMW/synthetic, aptamers).
  •  Kallikrein-related proteases (KLKs).
  • Proteolytic pathways in normal physiology and disease states (skin overdesquamation and inflammation, α-synuclein processing, neoplastic progression).
  • Animal models for preclinical testing of pharmaceutical compounds.
  • Production and engineering of recombinant proteins of pharmacological interest.

Current/Recent Collaborations

  • Alain Hovnanian, MD, PhD, Professor and Head INSERM UMR S1164 IHU Imagine - Institut des maladies génétiques - Université Paris Descartes, Paris, FRANCE Homepage:
  • Carlos López-Otín, PhD, Professor and Head Departamento de Bioquímica y Biología Molecular, Instituto Universitario de Oncología (IUOPA), Universidad de Oviedo, Oviedo, SPAIN
  • Eleftherios P. Diamandis MD, PhD, FRCP(C), FRSC, Professor Hold'em for Life Chair in Prostate Cancer Biomarkers,
Head of Clinical Biochemistry, 
Mount Sinai Hospital and University Health Network 
Professor & Head, Division of Clinical Biochemistry, 
Dept. of Laboratory Medicine & Pathobiology, University of Toronto, Toronto, Ontario, CANADA Homepage:
  • Kostas Vekrellis, Researcher B’ Division of Basic Neurosciences, Biomedical Research Foundation, Academy of Athens Athens, GREECE Homepage:
  • Oliver Schilling, PhD, ERC Awardee, Group Leader Emmy-Noether Research Fellow, Institute for Molecular Medicine and Cell Research, University of Freiburg, Freiburg, GERMANY Homepage: 
  • Guy Serre, MD, PhD, Professor, Directeur Unité Différenciation Epidermique et Autoimmunité Rhumatoïde (UMR 5165), UDEAR - UMR 5165 CNRS, 1056 INSERM, Université de Toulouse, Hôpital PURPAN, Place du Dr Baylac TSA 40031, Toulouse, FRANCE Homepage: Nathalie Jonca, Professor CNRS UMR 5165 - INSERM U1056 - Toulouse III University, CHU Purpan, Place du Dr Baylac - TSA 40031, Toulouse, FRANCE Homepage:
  • Andras Nagy, Pr ofessor and Head and Dr. Iacovos Michael Department of Molecular Genetics, University of Toronto and Mount Sinai Hospital and Samuel Lunenfeld Research Institute, Toronto, Ontario, CANADA Homepage:
  • George M Yousef, MD, PhD, FRCPC (Path), MSc, MBBCh, Professor Department of Laboratory Medicine, St. Michael's Hospital and Department of Laboratory Medicine and Pathobiology, University of Toronto, CANADA Homepage:
  • Evi S. Lianidou, Professor Laboratory of Analytical Chemistry, Department of Chemistry, 15771, University of Athens Homepage:
  • Stathopoulos George, MD, PhD, Associate Professor, ERC Awardee Department of Medicine, University of Patras, Rion-Patras, GREECE Homepage:
Organization Of Meetings - Conferences - Workshops

  • 5th General Meeting of the International Proteolysis Society (IPS2007) Conference and Cultural Center, University of Patras, 20-24 October 2007 >530 international participants; Chair: Georgia Sotiropoulou Αφίσα Συνεδρίου
  • Satellite Postgraduate Course on «Proteomics: Μethodologies and Αpplications»
  • Satellite Postgraduate Course on «Bioinformatics-Computational Methods in Biological Data Mining»
  • Satellite Postgraduate Course on «Enzyme Mechanisms and Kinetics» 19-20 October 2007, Department of Pharmacy, University of Patras


  1. Furio L#, Pampalakis G# , Michael IP, Nagy A, Sotiropoul ou G*, Hovnanian A.* (2015) Elimination of KLK5 reverses the hallmarks of Netherton syndrome. PLoS Genet 2015 Sep 21;11(9):e1005389.
  2. Pampalakis G, Politi AL, Papanastasiou A, Sotiropoulou G. (2015) Distinct cholesterogenic and lipidogenic gene expression patterns in ovarian cancer - A new pool of biomarkers. Genes Cancer in press.
  3. Pasic MD, Sotiropoulou G, Yousef GM. (2015) The miRNA-Kallikrein interactions: adding a new dimension. Cell Cycle 14: 691-692.
  4. Sidiropoulos KG, White NMA, Bui A, Ding Q, Boulos P, Pampalakis G, Khella H, Samuel JN, Sotiropoulou G, Yousef GM. (2014) Kallikrein-related peptidase 5 induces miRNA-mediated anti-oncogenic pathways in breast cancer. Oncoscience 1: 709-724.
  5. Ximerakis M, Pampalakis G, Roumeliotis TI, Sykioti V-S, Garbis SD, Stefanis L, Sotiropoulou G, Vekrellis K. (2014) Resistance of naturally secreted alpha-synuclein to proteolysis. FASEB J 28: 3146-3158.
  6. Pampalakis G, Obasuyi O, Papadodima O, Chatziioannou A, Zoumpourlis V, Sotiropoulou G.* (2014) The KLK5 protease suppresses breast cancer by repressing the mevalonate pathway. Oncotarget 5: 2390-2403.
  7. Sotiropoulou G, Pampalakis G. (2012) Targeting the kallikrein-related peptidases for drug development. Trends Pharmacol Sci 33: 623-634.
  8. Sotiropoulou G, Pampalakis G, Prosnikli E, Evangelatos GP, Livaniou E. (2012) Development and immunochemical evaluation of a novel chicken IgY antibody specific for KLK6. Chem Cent J 6: 148.
  9. Chimonidou M, Tzitzira A, Strati A, Sotiropoulou G, Sfikas C, Malamos N, Georgoulias V, Lianidou E. (2012) CST6 promoter methylation in circulating cell-free DNA of breast cancer patients. Clin Biochem 46: 235-240
  10. Kapasa M, Vlachakis D, Kostadima M, Sotiropoulou G, Kossida S. (2012) Towards the elucidation of the regulatory network guiding the insulin producing cells' differentiation. Genomics 100: 212-221.
  11. Chimonidou M, Strati A, Tzitzira A, Sotiropoulou G, Malamos N, Georgoulias V, Lianidou ES. (2011) DNA methylation of tumor suppressor and metastasis suppressor genes in circulating tumor cells. Clin Chem 57: 1169-1177.
  12. Arnold S, Pampalakis G, Kantiotou K, Silva D, Cortez C, Missailidis S, Sotiropoulou G. (2011) One round of SELEX for the generation of DNA aptamers directed against KLK6. Biol Chem 393: 343-353.
  13. Papanastasiou AD, Pampalakis G, Katsaros D,Sotiropoulou G. . (2011) Netrin-1 overexpression is predictive of ovarian malignancies. Oncotarget 2011 May 2 [Epub ahead of print]
  14. Pavlopoulou A, Pampalakis G, Michalopoulos I, Sotiropoulou G. (2010) Reconstruction of the evolutionary history of tissue kallikreins. PLoS ONE 5: e13781-13781.
  15. Lianidou ES, Mavroudis D, Sotiropoulou G, Aggelaki S, Pantel K. (2010) What’s new on Circulating Tumor Cells? A meeting report. Breast Cancer Res 12: 307-311.
  16. Sotiropoulou G, Pampalakis G. (2010) Evolving concepts of tissue kallikrein-related peptidases as bridges of immune function and proteolytic destruction of extracellular matrix. Biol Chem 391: 321-331.
  17. Sotiropoulou G, Pampalakis G, Diamandis EP. (2009) Functional roles of human kallikrein-related peptidases. J Biol Chem 284: 32989-32994.
  18. Pampalakis G, Diamandis EP, Katsaros D, Sotiropoulou G.(2010) Down-regulation of Dicer mRNA in ovarian cancer tissues provides a new potential biomarker. Clin Biochem 43: 324-327
  19. Pampalakis G, Diamandis EP, Katsaros D, Sotiropoulou G. (2009) Down-regulation of Dicer expression in ovarian cancer tissues. Clin. Biochem. 2009 Sep 24. [Epub ahead of print]
  20. Pampalakis G, Prosnikli E, Agalioti T, Vlahou A, Zoumpourlis V, Sotiropoulou G. (2009) A tumor protective role for human kallikrein-related peptidase 6 in breast cancer mediated by inhibition of epithelial-to-mesenchymal transition. Cancer Res. 69: 3779-3787.
  21. Sotiropoulou G, Pampalakis G, Lianidou ES, Mourelatos Z. (2009) Emerging roles of microRNAs as molecular switches in the integrated circuit of the cancer cell. RNA 15: 1443-1461.
  22. Kioulafa M, Balkouranidou I, Sotiropoulou G, Kaklamanis L, Mavroudis D, Georgoulias V, Lianidou ES. (2009) Methylation of cystatin M promoter in breast cancer is associated with unfavorable prognosis. Int. J. Cancer, in press
  23. Sotiropoulou G , Sommerhoff CP. (2008) Highlight on advances in proteolysis research. Biol. Chem. 389: 967-969.
  24. Pampalakis G, Scorilas A, Sotiropoulou G. (2008) Novel splice variants of prostate-specific antigen and applications in diagnosis of prostate cancer. Clin. Biochem. 41: 591-597
  25. Pampalakis G, Arampatzidou M, Amoutzias G, Kossida S, Sotiropoulou G. (2007) Identification and analysis of mammalian KLK6 orthologue genes for prediction of physiological substrates. Comput. Biol. Chem. 1776: 22-31
  26. Borgoño CA, Gavigan JA, Alves J, Bowles B, Harris JL, Sotiropoulou G, Diamandis EP (2007) Defining the extended substrate specificity of kallikrein 1-related peptidases. Biol. Chem. 388: 1215-1225.
  27. Pampalakis G,Sotiropoulou G. (2007) Tissue kallikrein proteolytic cascade pathways in normal physiology and cancer. BBA Reviews on Cancer 1776: 22-31.
  28. Borgoňo C, Michael IP, Komatsu N, Jayakumar A, Kapadia R, Clayman GL, Sotiropoulou G, Blaber M, Diamandis EP. (2007) A potential role for multiple tissue kallikrein serine proteases in epidermal desquamation: Regulation by lympho-epithelial Kazal-type inhibitor and digestion of desmoglein 1. J. Biol. Chem. 282: 3640-3652.
  29. Shaw JLV, Grass L, Sotiropoulou G, Diamandis EP. (2006) Development of an immunofluorometric assay for human kallikrein 15 (KLK15) and identification of KLK15 in tissues and biological fluids. Clin. Biochem. 40: 104-110.
  30. Borgoňo C, Michael IP, Komatsu N, Jayakumar A, Kapadia R, Clayman GL, Sotiropoulou G, Blaber M, Diamandis EP. (2006) A potential role for multiple tissue kallikrein serine proteases in epidermal desquamation: Regulation by lympho-epithelial Kazal-type inhibitor and digestion of desmoglein 1. Journal of Biological Chemistry Dec 11 [Epub ahead of print]
  31. Shaw JLV, Grass L, Sotiropoulou G, Diamandis EP. (2006) Development of an immunofluorometric assay for human kallikrein 15 (KLK15) and identification of KLK15 in tissues and biological fluids. Clinical Biochemistry 40: 104-110. Epub 2006 Aug 25
  32. Pampalakis G, Diamandis EP and Sotiropoulou G. (2006) The epigenetic basis for the aberrant expression of kallikreins in human cancers. Biological Chemistry, 387: 795-799.
  33. Michael IP, Pampalakis G, Mikolajczyk SD, Malm J, Sotiropoulou G, Diamandis EP. (2006) Involvement of human kallikrein 5 (hK5) in proteolytic cascade pathway culminating in seminal plasma liquefaction and prostate cancer progression. Journal of Biological Chemistry 281: 12743-12750.
  34. Lundwall Ǻ, Band V, Blaber M, Clements J, Courty Y, Diamandis EP, Fritz H, Lilja H, Malm J, Maltais LJ, Olsson AY, Petraki C, Scorilas A, Sotiropoulou G, Stenman U-H, Stephan C, Talieri M, Yousef GM. (2006) A comprehensive nomenclature for serine proteases with homology to the tissue kallikrein. Biological Chemistry, 387: 637-641.
  35. Pampalakis G, Sotiropoulou G. (2006) Multiple mechanisms underlie the aberrant expression of the human kallikrein 6 gene in breast cancer. Biological Chemistry, 387: 773-782.
  36. Sidiropoulos M, Pampalakis G, Sotiropoulou G, Katsaros D, Diamandis EP (2005) Down-Regulation of human kallikrein 10 (KLK10/NES1) by CpG island hypermethylation in breast, ovarian and prostate cancers. Tumor Biology 26: 324-336.
  37. Obiezu CV, Shan SJ, Soosaipillai A, Luo LY, Grass L, Sotiropoulou G, Petraki CD, Papanastasiou PA, Levesque MA, Diamandis EP. (2005) Human kallikrein 4: quantitative study in tissues and evidence for its secretion into biological fluids. Clinical Chemistry 51: 1432-1442.
  38. Michael IP, Sotiropoulou G, Pampalakis G, Magklara A, Ghosh M, Wasney G, Diamandis EP. (2005) Biochemical and enzymatic characterization of human kallikrein 5 (hK5), a novel serine protease potentially involved in cancer progression. Journal of Biological Chemistry 280: 14628-14635.
  39. Ghosh MC, Grass L, Soosaipillai A, Sotiropoulou G, Diamandis EP. (2004) Human kallikrein 6 degrades extracellular matrix proteins and may enhance the metastatic potential of tumour cells. Tumour Biology 25: 193-199.
  40. Pampalakis G, Kurlender L, Diamandis EP, Sotiropoulou G. (2004) Cloning and characterization of novel isoforms of the human kallikrein 6 gene. Biochemical and Biophysical Research Communications 320: 54-61.
  41. Bayés A, Tsetsenis T, Ventura S, Avilés FX, Vendrell J, Sotiropoulou G. (2004) Human kallikrein 6 activity is regulated via an autoproteolytic mechanism of activation/inactivation. Biological Chemistry 385: 517-524.
  42. Ghosh MC, Grass L, Soosaipillai A, Sotiropoulou G, Diamandis EP. (2004) Human kallikrein 6 degrades extracellular matrix proteins and may enhance the metastatic potential of tumour cells. Tumour Biology 25: 193-199.
  43. Shridhar R, Zhang J, Song J, Booth BA, Kevil CG, Sotiropoulou G, Sloane BF, Keppler D. (2004) Cystatin M suppresses the malignant phenotype of human MDA-MB-435S cells. Oncogene 23: 2206-2215.
  44. Magklara A, Mellati AA, Wasney GA, Little SP, Sotiropoulou G, Becker GW, Diamandis EP. (2003) Characterization of the enzymatic activity of human kallikrein 6: Autoactivation, substrate specificity, and regulation by inhibitors. Biochem Biophys Res Commun 307: 948-955.
  45. Sotiropoulou G, Rogakos V, Tsetsenis T, Pampalakis G, Zafeiropoulos N, Simillides G, Yiotakis A, Diamandis EP. (2003) Emerging interest in the kallikrein gene family for understanding and diagnosing cancer. Oncology Research 13: 381-391.
  46. Kapadia C, Chang A, Sotiropoulou G, Yousef GM, Grass L, Soosaipillai A, Xing X, Howarth DHC, Diamandis EP. (2003) Human kallikrein 13: Production and purification of recombinant protein, monoclonal and polyclonal antibodies and development of a sensitive and specific immunofluorometric assay. Clinical Chemistry 49:77-86.
  47. Gomis-Rüth FX, Bayés A, Sotiropoulou G, Pampalakis G, Tsetsenis T, Vigellas V, Avilés FX, and Coll M. (2002) The structure of prozyme unveils a novel activation mechanism for the human kallikrein family. The Journal of Biological Chemistry 277: 27273-27281.
  48. Lin R, Nagai Y, Sladek R, Bastien Y, Ho J, Petrecca K, Sotiropoulou G, Diamandis EP, Hudson TJ, White JH. (2002) Expression profiling in squamous carcinoma cells reveals pleiotropic effects of vitamin D3 analog EB1089 signalling on cell proliferation, differentiation, and immune system regulation. Molecular Endocrinology 16: 1243-1256.
  49. Sotiropoulou G, Kono M, Anisowicz A, Stenman G, Tsuji S, Sager R. (2002) Identification and functional characterization of a human GalNAc a2,6-sialyltransferase with altered expression in breast cancer. Molecular Medicine 8: 42-55.
  50. Zeeuwen PL, Van Vlijmen-Willems IM, Jansen BJ, Sotiropoulou G, Curfs JH, Meis JF, Janssen JJ, Van Ruissen F, Schalkwijk J. (2001) Cystatin M/E expression is restricted to differentiated epidermal keratinocytes and sweat glands: a new skin-specific proteinase inhibitor that is a target for cross-linking by transglutaminase. Journal of Investigative Dermatology 116: 693-701.
  51. Diamandis EP, Yousef GM, Soosaipillai AR, Grass L, Porter A, Little S, Sotiropoulou G. (2000) Immunofluorometric assay of human kallikrein 6 (zyme/protease M/neurosin) and preliminary clinical applications. Clinical Biochemistry 33: 369-375.
  52. Dionyssopoulou H, Mouzaki A, Slootstra J, Puijk W, Meloen R, Cordopatis P, Sotiropoulou G. (2000) Synthetic peptides as putative therapeutic agents in transplantation medicine: application of PEPSCAN to the identification of functional sequences in the extracellular domain of the interleukin-2 receptor beta chain (IL-2Rbeta). Journal of Immunological Methods 241: 83-95.
  53. Yousef GM, Luo LY, Scherer SW, Sotiropoulou G, Diamandis EP. (1999) Molecular characterization of zyme/protease M/neurosin, a hormonally-regulated kallikrein-like serine protease. Genomics 62: 251-259.
  54. Anisowicz A, Sotiropoulou G, Sager R. (1999) Re-expression of the SPR1 gene in breast carcinomas by phorbol 12-myristate 13-acetate or UV irradiation is mediated by the AP-1 binding site in the SPR1 promoter. Molecular Medicine 5: 526-541.
  55. Sotiropoulou G, Anisowicz A, Sager R. (1997) Identification, cloning and characterization of cystatin M, a novel cysteine proteinase inhibitor, down-regulated in breast cancer. Journal of Biological Chemistry 272: 903-910.
  56. Stenman G, Astrom AK, Roijer E, Sotiropoulou G, Zhang M, Sager R. (1997) Assignment of a novel cysteine proteinase inhibitor (CST6) to 11q13 by fluorescence in situ hybridization. Cytogenetics and Cell Genetics 76: 45-46.
  57. Anisowicz A, Sotiropoulou G, Stenman G, Mok SC, Sager R. (1996) A novel protease homolog diferentially expressed in breast and ovarian cancer. Molecular Medicine 2: 624-636.
  58. Sotiropoulou G, Anisowicz A, Ryan K, Sager R. (1995) Isolation of a novel protease inhibitor involved in breast cancer and senescence». International Journal of Oncology Suppl. 7: 969.
  59. Sager R, Sheng S, Anisowicz A, Sotiropoulou G, Zou Z, Swisshelm K, Hendrix M, Thor A, Ryan K, Rafidi K, Seftor E. (1994) RNA genetics of breast cancer: maspin as a paradigm. Cold Spring Harbor Symposia of Quantitative Biology 59: 537-546.
  60. Sager R, Anisowicz A, Neveu M, Liang P, Sotiropoulou G. (1993) Identification by differential display of alpha 6 integrin as a candidate tumor suppressor gene. FASEB Journal 7: 964-970.




Textbooks-Greek Editions

"Pharmaceutical Biotechnology. Fundamentals and Applications"
Daan JA Crommelin, Robert D Sindelar, Bernd Meibohm (Informa, 2008; 3rd Edition) Τίτλος Ελληνικής Έκδοσης: "Φαρμακευτική Βιοτεχνολογία. Βασικές Αρχές και Πρακτικές Εφαρμογές" Πανεπιστημιακές Εκδόσεις Παρισιάνου, 2011, A Tsiftsoglou, G Sotiropoulou

Editorial Group Member

  1. "The Cell: A Molecular Approach" (5th Edition) Cooper GM, Hausman RE (Sinauer, 2009) Greek Edition: "To Κύτταρο: Μια Μοριακή Προσέγγιση" Ακαδημαϊκές Εκδόσεις Ι. Μπάσδρα και ΣΙΑ ΟΕ, 2011
  2. "Molecular Biology of the Gene" (6th edition) James D Watson, Tania A Baker, Stephen P Bell, Alexander Gann, Michael Levine, Richard Losick (CSHLP, Pearson, Benjamin Cummings, Prentice Hall, 2008) Greek Edition: "Μοριακή Βιολογία του Γονιδίου" Utopia Publishing, 2010
  3.  "Recombinant DNA. Genes and Genomes – A Short Course" James Watson, Amy Caudy, Richard Myers, Jan Witkowski WH Freeman and Company, Cold Spring Harbour Laboratory Press (2007) Greek Edition: "Ανασυνδυασμένο DNA. Γονίδια και Γονιδιώματα - Μια Συνοπτική Παρουσίαση" Ακαδημαϊκές Εκδόσεις Ι. Μπάσδρα και ΣΙΑ ΟΕ, 2007

 Handouts for Laboratory Training

  1. G Sotiropoulou, I Zarkadis (Patras 2007) Laboratory Exercises for the Undergraduate Course "Pharmaceutical Biotechnology"
  2. G Sotiropoulou, G Pampalakis (Patras 2010; 2006-2009 earlier versions) Laboratory Exercises for the Undergraduate Course "Molecular Biology-Genetics"

Distance Learning

Production of Alternative Teaching Material in HYPERTEXT format (EAP/GOU: KFE53) Topics: Cell division and cancer: Regulation of cell cycle, apoptosis, oncogenes, and tumor suppressor genes. Techniques and methodologies for analysis of mutations.


Undergraduate Courses:

  • Cell Biology (PHA-Y-124)
  • Pharmaceutical Biotechnology (PHA-Y-414)

Postgraduate Course:

  • Pharmaceutical Biotechnology (PST-F-104)

Recommended Textbooks:

Cell Biology

"Essential Cell Biology" by Alberts B, Bray D, Hopkin K, Johnson A, Lewis J, Raff M, Roberts K, Walter P. [Greek Edition: "Βασικές Αρχές Κυτταρικής Βιολογίας", Εκδόσεις ΠΑΣΧΑΛΙΔΗ, 2006]
"The Cell: A Molecular Approach"
by Geoffrey M. Cooper and Robert Hausman, 5th Edition (2009) [Greek Edition: "Το Κύτταρο: Μια Μοριακή Προσέγγιση", Εκδόσεις Ι. ΜΠΑΣΔΡΑ, 2011]

Suggested Publications for Further Reading:

Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 144: 646-674, 2011
Lord CJ, Ashworth A. Biology-driven cancer drug development: back to the future. BMC Biol 8: 38, 2010

Pharmaceutical Biotechnology

"Pharmaceutical Biotechnology. Fundamentals and Applications" by Daan J.A. Crommelin, Robert D. Sindelar, Bernd Meibohm, 3rd Edition, Informa Healthcare (2008) 
 [Greek Edition: "Φαρμακευτική Βιοτεχνολογία. Βασικές Αρχές και Πρακτικές Εφαρμογές", Εκδόσεις Παρισιάνου, 2011, Επιμέλεια Ελληνικής Έκδοσης: Αστέριος Σ. Τσιφτσόγλου και Γεωργία Σωτηροπούλου]

"Recombinant DNA. Genes and Genomes-A Short Course" by James Watson, Amy Caudy, Richard Myers, Jan Witkowski, W. H. Freeman and Company, Cold Spring Harbor Laboratory Press, 3rd Edition (2007) [Greek Edition: "Ανασυνδυασμένο DNA. Γονίδια και Γονιδιώματα - Μια Συνοπτική Παρουσίαση", Εκδόσεις Ι. ΜΠΑΣΔΡΑ, 2007]

"Pharmaceutical Biotechnology - Laboratory Exercises" by Sotiropoulou G, Zarkadis IK. Available in eclass











"Φαρμακευτική Βιοτεχνολογία: Από το χθες στο σήμερα" 

ΣΥΝΕΝΤΕΥΞΗ : Η επιστήμονας Γεωργία Σωτηροπούλου μιλά στο
30 Δεκεμβρίου 2013, 14:00 | ΠΟΡΤΡΑΙΤΑ 



Ώρες γραφείου: Τρίτη 14:30-16:30 μ.μ
                            Τετάρτη 12:00-13:00 μ.μ